November 18, 2010Heart
Non-invasive evaluation of myocardial fibrosis: implications for the clinician
Key result
Novel imaging and serum biomarkers enable accurate non-invasive detection of myocardial fibrosis to guide prognosis.
Why the study?
Myocardial fibrosis is a key determinant of treatment response and prognosis in cardiac conditions, but ante mortem detection was limited to endomyocardial biopsy with associated risks and sampling error.
Can novel cardiac imaging techniques and serum assays accurately detect and quantify myocardial fibrosis compared to endomyocardial biopsy?
Structured PICO
Can novel cardiac imaging techniques and serum assays accurately detect and quantify myocardial fibrosis compared to endomyocardial biopsy?
P
Population
Patients with cardiac conditions where myocardial fibrosis is a determinant of prognosis and treatment response
I
Intervention
Non-invasive evaluation of myocardial fibrosis using novel cardiac imaging techniques and serum assays
C
Comparator
Endomyocardial biopsy (historical standard)
O
Outcome
Detection and quantification of myocardial fibrosissurrogate
Non-invasive imaging and serum assays provide an accurate, lower-risk alternative to endomyocardial biopsy for evaluating myocardial fibrosis, offering valuable prognostic and therapeutic insights.
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Noninvasive fibrosis detection may refine prognosis and treatment response; leaves open prospective validation before practice change.
Cite This Study
Leong et al. (2010) conducted a review in Myocardial fibrosis. Novel cardiac imaging techniques and serum assays vs. Endomyocardial biopsy was evaluated. Novel cardiac imaging techniques and serum assays permit accurate non-invasive detection of myocardial fibrosis, yielding new insights into disease prognosis and response to treatment.